 High-dose cisplatin dacarbazine treatment metastatic melanoma combination cisplatin dacarbazine DTIC active metastatic melanoma response rates regimen Phase II study dose intensity cisplatin Twenty-two patients patients cisplatin days DTIC days excessive toxicity protocol cisplatin day DTIC day days regimen overall response rate partial complete responses CR median duration response months CR sustained unmaintained remission excess years patients regimen High-dose cisplatin DTIC schedule effective well-tolerated therapy metastatic melanoma